Expression of the potential therapeutic target claudin-18.2 is frequently decreased in gastric cancer: results from a large Caucasian cohort study
Sign Up to like & getrecommendations! Published in 2019 at "Virchows Archiv"
DOI: 10.1007/s00428-019-02624-7
Abstract: Gastric cancer (GC) is frequently diagnosed and treated in advanced tumour stages with poor prognosis. Recent studies have identified isoform 2 of the tight junction protein claudin-18 (CLDN18.2) as a promising target in GC therapy.… read more here.
Keywords: expression cldn18; gastric cancer; target; cohort ... See more keywords
Claudin 18 immunohistochemistry in cholangiocarcinoma
Sign Up to like & getrecommendations! Published in 2025 at "Journal of Gastrointestinal Oncology"
DOI: 10.21037/jgo-2024-925
Abstract: Background Monoclonal antibodies against claudin (CLDN) 18.2 (a component of tight junctions) in gastric epithelial cells are an emerging therapeutic option for patients with advanced gastric and esophageal adenocarcinoma. Phase 2 and 3 trials have… read more here.
Keywords: cholangiocarcinomas; cldn18; high expression; expression cldn18 ... See more keywords